These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21777888)

  • 21. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials.
    Tanimoto S; Serruys PW; Thuesen L; Dudek D; de Bruyne B; Chevalier B; Ormiston JA
    Catheter Cardiovasc Interv; 2007 Oct; 70(4):515-23. PubMed ID: 17503509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.
    Serruys PW; Katagiri Y; Sotomi Y; Zeng Y; Chevalier B; van der Schaaf RJ; Baumbach A; Smits P; van Mieghem NM; Bartorelli A; Barragan P; Gershlick A; Kornowski R; Macaya C; Ormiston J; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Windecker S; Byrne RA; Räber L; van Geuns RJ; Mintz GS; Onuma Y
    J Am Coll Cardiol; 2017 Jul; 70(1):60-74. PubMed ID: 28662808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
    Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
    J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials.
    Brugaletta S; Gomez-Lara J; Diletti R; Farooq V; van Geuns RJ; de Bruyne B; Dudek D; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):219-28. PubMed ID: 21563288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.
    Tröbs M; Achenbach S; Röther J; Klinghammer L; Schlundt C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):872-880. PubMed ID: 27142643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
    Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C
    JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
    Diletti R; Onuma Y; Farooq V; Gomez-Lara J; Brugaletta S; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Smits P; Koolen J; Meredith I; Li D; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    J Am Coll Cardiol; 2011 Jul; 58(3):258-64. PubMed ID: 21737016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
    Fam JM; Felix C; van Geuns RJ; Onuma Y; Van Mieghem NM; Karanasos A; van der Sijde J; De Paolis M; Regar E; Valgimigli M; Daemen J; de Jaegere P; Zijlstra F; Diletti R
    EuroIntervention; 2016 May; 12(1):30-7. PubMed ID: 27173859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries.
    Lane JP; Perkins LE; Sheehy AJ; Pacheco EJ; Frie MP; Lambert BJ; Rapoza RJ; Virmani R
    JACC Cardiovasc Interv; 2014 Jun; 7(6):688-95. PubMed ID: 24835327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fracture of Bioresorbable Vascular Scaffold After Side-Branch Balloon Dilation in Bifurcation Coronary Narrowings.
    Pan M; Romero M; Ojeda S; Suarez de Lezo J; Segura J; Mazuelos F; Martin P; Medina A; Suarez de Lezo J
    Am J Cardiol; 2015 Oct; 116(7):1045-9. PubMed ID: 26243578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of a bioresorbable vascular scaffold to complex lesions.
    Meincke F; Kuck KH; Bergmann MW
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):774-8. PubMed ID: 23907893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
    Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
    J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is bioresorbable vascular scaffold acute recoil affected by baseline renal function and scaffold selection?
    Gunes HM; Yılmaz FK; Gokdeniz T; Demir GG; Guler E; Guler GB; Karaca O; Cakal B; İbişoğlu E; Boztosun B
    Int J Cardiol; 2016 Dec; 224():388-393. PubMed ID: 27681252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
    Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
    JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.